AP9901720A0 - Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitors. - Google Patents

Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitors.

Info

Publication number: AP9901720A0
Authority: AP; ARIPO
Prior art keywords: alpha; treatment; diabetes; thiazolidinedione; glucosidase inhibitors
Prior art date: 1997-06-18

Application number

APAP/P/1999/001720A

Other languages

English (en)

Inventor

Stephen Alistair Smith

Original Assignee

Smithkline Beecham Plc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-06-18

Filing date

1998-06-15

Publication date

1999-12-31

1997-06-18 Priority claimed from GBGB9712865.6A external-priority patent/GB9712865D0/en

1998-03-27 Priority claimed from GBGB9806708.5A external-priority patent/GB9806708D0/en

1998-06-15 Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc

1999-12-31 Publication of AP9901720A0 publication Critical patent/AP9901720A0/en

Links

206010012601 diabetes mellitus Diseases 0.000 title abstract 3
229940077274 Alpha glucosidase inhibitor Drugs 0.000 title abstract 2
239000003888 alpha glucosidase inhibitor Substances 0.000 title abstract 2
ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 title 1
229940123464 Thiazolidinedione Drugs 0.000 title 1
241000124008 Mammalia Species 0.000 abstract 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
102000004877 Insulin Human genes 0.000 abstract 1
108090001061 Insulin Proteins 0.000 abstract 1
230000002058 anti-hyperglycaemic effect Effects 0.000 abstract 1
239000003795 chemical substances by application Substances 0.000 abstract 1
229940125396 insulin Drugs 0.000 abstract 1
231100000252 nontoxic Toxicity 0.000 abstract 1
230000003000 nontoxic effect Effects 0.000 abstract 1
231100000489 sensitizer Toxicity 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Molecular Biology (AREA)
Emergency Medicine (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Obesity (AREA)
Chemical Kinetics & Catalysis (AREA)
Endocrinology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Plural Heterocyclic Compounds (AREA)
Fodder In General (AREA)

APAP/P/1999/001720A 1997-06-18 1998-06-15 Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitors. AP9901720A0 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GBGB9712865.6A GB9712865D0 (en)	1997-06-18	1997-06-18	Novel method of treatment
GBGB9806708.5A GB9806708D0 (en)	1998-03-27	1998-03-27	Novel method
PCT/EP1998/003691 WO1998057635A1 (fr)	1997-06-18	1998-06-15	Traitement du diabete a l'aide de thiazolidinedione et d'un inhibiteur des alpha-glucosidases

Publications (1)

Publication Number	Publication Date
AP9901720A0 true AP9901720A0 (en)	1999-12-31

Family

ID=26311746

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
APAP/P/1999/001720A AP9901720A0 (en)	1997-06-18	1998-06-15	Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitors.

Country Status (24)

Country	Link
EP (1)	EP0975343A1 (fr)
JP (1)	JP2001523271A (fr)
KR (1)	KR20010013845A (fr)
CN (1)	CN1274282A (fr)
AP (1)	AP9901720A0 (fr)
AR (2)	AR014881A1 (fr)
AU (1)	AU8799998A (fr)
BG (1)	BG103966A (fr)
BR (1)	BR9810186A (fr)
CA (1)	CA2294134A1 (fr)
CO (1)	CO4940453A1 (fr)
DZ (1)	DZ2519A1 (fr)
EA (1)	EA200000040A1 (fr)
IL (1)	IL133138A0 (fr)
MA (1)	MA26510A1 (fr)
NO (1)	NO996270L (fr)
NZ (1)	NZ501345A (fr)
OA (1)	OA11631A (fr)
PE (1)	PE89199A1 (fr)
PL (1)	PL337577A1 (fr)
SK (1)	SK179499A3 (fr)
TR (1)	TR199903072T2 (fr)
UY (1)	UY25051A1 (fr)
WO (1)	WO1998057635A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7045519B2 (en)	1998-06-19	2006-05-16	Chiron Corporation	Inhibitors of glycogen synthase kinase 3
HRP20010773B1 (en)	1999-04-23	2005-06-30	Smithkline Beecham P.L.C.	Thiazolidinedione derivative and its use as antidiabetic
US20030045553A1 (en)	2001-04-04	2003-03-06	Bussolari Jacqueline C.	Combination therapy comprising glucose reabsorption inhibitors and PPAR modulators
JP4590158B2 (ja)	2001-04-04	2010-12-01	オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド	グルコース再吸収阻害剤およびレチノイド−ｘ受容体モジュレーターを含んで成る併用療法
FR2832930A1 (fr) *	2001-12-03	2003-06-06	Lipha	Composition pharmaceutique comprenant un inhibiteur d'alpha-glucosidase et un derive de thiazolidinedione et son utilisation pour la preparation de medicaments destines a traiter le diabete
JP2004067575A (ja) *	2002-08-06	2004-03-04	Yaizu Suisankagaku Industry Co Ltd	糖尿病治療薬効果促進剤
CN101121004B (zh) *	2006-08-08	2010-07-21	鲁南制药集团股份有限公司	含有胰岛素增敏剂和米格列醇的药物组合物
CN101584705B (zh) *	2008-05-24	2010-10-27	鲁南制药集团股份有限公司	一种治疗糖尿病及其并发症的药物组合物
CN101584688B (zh) *	2008-05-24	2010-11-10	鲁南制药集团股份有限公司	一种治疗糖尿病及其并发症的药物组合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH06510286A (ja) *	1991-08-26	1994-11-17	ファルマシア・アンド・アップジョン・カンパニー	３−グアニジノプロピオン酸およびピオグリタゾン、グリベンクラミドまたはグリメピリドを含有する医薬組成物
US5917052A (en) *	1994-09-28	1999-06-29	Shaman Pharmaceuticals, Inc.	Hypoglycemic agent from cryptolepis
TW438587B (en) *	1995-06-20	2001-06-07	Takeda Chemical Industries Ltd	A pharmaceutical composition for prophylaxis and treatment of diabetes

1998
- 1998-06-15 WO PCT/EP1998/003691 patent/WO1998057635A1/fr not_active Ceased
- 1998-06-15 PL PL98337577A patent/PL337577A1/xx unknown
- 1998-06-15 JP JP50375699A patent/JP2001523271A/ja not_active Ceased
- 1998-06-15 AP APAP/P/1999/001720A patent/AP9901720A0/en unknown
- 1998-06-15 AU AU87999/98A patent/AU8799998A/en not_active Abandoned
- 1998-06-15 CN CN98806319A patent/CN1274282A/zh active Pending
- 1998-06-15 EA EA200000040A patent/EA200000040A1/ru unknown
- 1998-06-15 EP EP98939513A patent/EP0975343A1/fr not_active Withdrawn
- 1998-06-15 SK SK1794-99A patent/SK179499A3/sk unknown
- 1998-06-15 KR KR1019997011866A patent/KR20010013845A/ko not_active Withdrawn
- 1998-06-15 IL IL13313898A patent/IL133138A0/xx unknown
- 1998-06-15 BR BR9810186-2A patent/BR9810186A/pt not_active IP Right Cessation
- 1998-06-15 TR TR1999/03072T patent/TR199903072T2/xx unknown
- 1998-06-15 CA CA002294134A patent/CA2294134A1/fr not_active Abandoned
- 1998-06-17 MA MA25121A patent/MA26510A1/fr unknown
- 1998-06-17 AR ARP980102885A patent/AR014881A1/es unknown
- 1998-06-17 AR ARP980102882A patent/AR013352A1/es unknown
- 1998-06-17 DZ DZ980129A patent/DZ2519A1/fr active
- 1998-06-18 CO CO98034648A patent/CO4940453A1/es unknown
- 1998-06-18 UY UY25051A patent/UY25051A1/es not_active Application Discontinuation
- 1998-06-18 PE PE1998000536A patent/PE89199A1/es not_active Application Discontinuation
- 1998-07-15 NZ NZ501345A patent/NZ501345A/en unknown
1999
- 1999-12-08 BG BG103966A patent/BG103966A/bg unknown
- 1999-12-17 OA OA9900295A patent/OA11631A/en unknown
- 1999-12-17 NO NO996270A patent/NO996270L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
JP2001523271A (ja)	2001-11-20
WO1998057635A1 (fr)	1998-12-23
UY25051A1 (es)	2000-09-29
KR20010013845A (ko)	2001-02-26
NO996270D0 (no)	1999-12-17
SK179499A3 (en)	2000-11-07
CO4940453A1 (es)	2000-07-24
AR014881A1 (es)	2001-04-11
PL337577A1 (en)	2000-08-28
MA26510A1 (fr)	2004-12-20
OA11631A (en)	2004-11-22
EA200000040A1 (ru)	2000-08-28
IL133138A0 (en)	2001-03-19
CA2294134A1 (fr)	1998-12-23
PE89199A1 (es)	1999-10-23
NZ501345A (en)	2001-10-26
EP0975343A1 (fr)	2000-02-02
BR9810186A (pt)	2000-08-08
TR199903072T2 (xx)	2000-07-21
AR013352A1 (es)	2000-12-27
AU8799998A (en)	1999-01-04
BG103966A (bg)	2000-07-31
DZ2519A1 (fr)	2003-02-01
NO996270L (no)	1999-12-17
CN1274282A (zh)	2000-11-22

Publication	Publication Date	Title
AP2002002703A0 (en)	2002-12-31	Combinations of depeptidyl peptidase IV inhibitors and other antidiabetic agents for the treatment of diadetes mellitus.
EP1787646A3 (fr)	2007-10-03	Nouveau procédé de traitement
MY155219A (en)	2015-09-30	Treatment of diabetes with thiazolidinedione, insulin secretagogue and biguanide
AP2001002291A0 (en)	2001-12-31	Novel method of treatment.
NO20083276L (no)	2000-02-17	Behandling av diabetes med tiazolidindion og sulfonylurea
TR199903095T2 (xx)	2000-08-21	Diabetin roziglitazon ve ins�lin ile tedavisi.
AP2000001735A0 (en)	2000-01-16	Treatment of diabetes with thiazolidinedione insulin secretagogue and alpha glucocidase inhibitor.
NO996270L (no)	1999-12-17	Behandling av diabetes med tiazolidindion og <alfa>- glukosidaseinhibitor
MY138246A (en)	2009-05-29	Treatment of diabetes with thiazolidione and sulphonylurea.
HK1041201A1 (zh)	2002-07-05	貝塔激動劑和抗糖尿病製劑的配伍
WO2001047509A3 (fr)	2002-09-12	Procede de traitement
NZ503862A (en)	2003-01-31	Use of insulin sensitisers (especially thiazolidinediones) for the treatment of hyperglycaemia
YU28700A (sh)	2003-10-31	Upotreba potencijatora osetljivosti na insulin u proizvodnji leka za lečenje hiperglikemije
ECSP982541A (es)	1999-02-11	Nuevo metodo de tratamiento ii
PL327472A1 (en)	1998-12-07	Nitrogen oxide (no) synthase inhibitor for use in treatment or polphylaxy of type ii diabetes
MY118982A (en)	2005-02-28	Method of reducing tissue damage associated with ischemia
ECSP982592A (es)	1999-02-22	Nuevo metodo de tratamiento v
ECSP982542A (es)	1999-02-11	Nuevo metodo de tratamiento iii
ECSP982593A (es)	1999-02-22	Nuevo metodo de tratamiento vi
MX9701533A (es)	1998-06-30	Procedimiento para reducir lesiones en tejidos asociadas con isquemia no cardiaca.